Copyright Reports & Markets. All rights reserved.

Global Janus Kinase (JAK) Inhibitors Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Janus Kinase (JAK) Inhibitors
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Janus Kinase (JAK) Inhibitors by Type
    • 1.3.1 Overview: Global Janus Kinase (JAK) Inhibitors Market Size by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Global Janus Kinase (JAK) Inhibitors Consumption Value Market Share by Type in 2023
    • 1.3.3 Ruxolitinib
    • 1.3.4 Tofacitinib
    • 1.3.5 Oclacitinib
    • 1.3.6 Baricitinib
    • 1.3.7 Peficitinib
  • 1.4 Global Janus Kinase (JAK) Inhibitors Market by Application
    • 1.4.1 Overview: Global Janus Kinase (JAK) Inhibitors Market Size by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Autoimmune Disorders
    • 1.4.3 Oncology
  • 1.5 Global Janus Kinase (JAK) Inhibitors Market Size & Forecast
  • 1.6 Global Janus Kinase (JAK) Inhibitors Market Size and Forecast by Region
    • 1.6.1 Global Janus Kinase (JAK) Inhibitors Market Size by Region: 2019 VS 2023 VS 2030
    • 1.6.2 Global Janus Kinase (JAK) Inhibitors Market Size by Region, (2019-2030)
    • 1.6.3 North America Janus Kinase (JAK) Inhibitors Market Size and Prospect (2019-2030)
    • 1.6.4 Europe Janus Kinase (JAK) Inhibitors Market Size and Prospect (2019-2030)
    • 1.6.5 Asia-Pacific Janus Kinase (JAK) Inhibitors Market Size and Prospect (2019-2030)
    • 1.6.6 South America Janus Kinase (JAK) Inhibitors Market Size and Prospect (2019-2030)
    • 1.6.7 Middle East and Africa Janus Kinase (JAK) Inhibitors Market Size and Prospect (2019-2030)

2 Company Profiles

  • 2.1 Astellas Pharma, Inc.
    • 2.1.1 Astellas Pharma, Inc. Details
    • 2.1.2 Astellas Pharma, Inc. Major Business
    • 2.1.3 Astellas Pharma, Inc. Janus Kinase (JAK) Inhibitors Product and Solutions
    • 2.1.4 Astellas Pharma, Inc. Janus Kinase (JAK) Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Astellas Pharma, Inc. Recent Developments and Future Plans
  • 2.2 Eli Lilly and Co.
    • 2.2.1 Eli Lilly and Co. Details
    • 2.2.2 Eli Lilly and Co. Major Business
    • 2.2.3 Eli Lilly and Co. Janus Kinase (JAK) Inhibitors Product and Solutions
    • 2.2.4 Eli Lilly and Co. Janus Kinase (JAK) Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Eli Lilly and Co. Recent Developments and Future Plans
  • 2.3 Incyte Corp.
    • 2.3.1 Incyte Corp. Details
    • 2.3.2 Incyte Corp. Major Business
    • 2.3.3 Incyte Corp. Janus Kinase (JAK) Inhibitors Product and Solutions
    • 2.3.4 Incyte Corp. Janus Kinase (JAK) Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Incyte Corp. Recent Developments and Future Plans
  • 2.4 Novartis AG
    • 2.4.1 Novartis AG Details
    • 2.4.2 Novartis AG Major Business
    • 2.4.3 Novartis AG Janus Kinase (JAK) Inhibitors Product and Solutions
    • 2.4.4 Novartis AG Janus Kinase (JAK) Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 Novartis AG Recent Developments and Future Plans
  • 2.5 Pfizer Inc.
    • 2.5.1 Pfizer Inc. Details
    • 2.5.2 Pfizer Inc. Major Business
    • 2.5.3 Pfizer Inc. Janus Kinase (JAK) Inhibitors Product and Solutions
    • 2.5.4 Pfizer Inc. Janus Kinase (JAK) Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 Pfizer Inc. Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Janus Kinase (JAK) Inhibitors Revenue and Share by Players (2019-2024)
  • 3.2 Market Share Analysis (2023)
    • 3.2.1 Market Share of Janus Kinase (JAK) Inhibitors by Company Revenue
    • 3.2.2 Top 3 Janus Kinase (JAK) Inhibitors Players Market Share in 2023
    • 3.2.3 Top 6 Janus Kinase (JAK) Inhibitors Players Market Share in 2023
  • 3.3 Janus Kinase (JAK) Inhibitors Market: Overall Company Footprint Analysis
    • 3.3.1 Janus Kinase (JAK) Inhibitors Market: Region Footprint
    • 3.3.2 Janus Kinase (JAK) Inhibitors Market: Company Product Type Footprint
    • 3.3.3 Janus Kinase (JAK) Inhibitors Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Janus Kinase (JAK) Inhibitors Consumption Value and Market Share by Type (2019-2024)
  • 4.2 Global Janus Kinase (JAK) Inhibitors Market Forecast by Type (2025-2030)

5 Market Size Segment by Application

  • 5.1 Global Janus Kinase (JAK) Inhibitors Consumption Value Market Share by Application (2019-2024)
  • 5.2 Global Janus Kinase (JAK) Inhibitors Market Forecast by Application (2025-2030)

6 North America

  • 6.1 North America Janus Kinase (JAK) Inhibitors Consumption Value by Type (2019-2030)
  • 6.2 North America Janus Kinase (JAK) Inhibitors Consumption Value by Application (2019-2030)
  • 6.3 North America Janus Kinase (JAK) Inhibitors Market Size by Country
    • 6.3.1 North America Janus Kinase (JAK) Inhibitors Consumption Value by Country (2019-2030)
    • 6.3.2 United States Janus Kinase (JAK) Inhibitors Market Size and Forecast (2019-2030)
    • 6.3.3 Canada Janus Kinase (JAK) Inhibitors Market Size and Forecast (2019-2030)
    • 6.3.4 Mexico Janus Kinase (JAK) Inhibitors Market Size and Forecast (2019-2030)

7 Europe

  • 7.1 Europe Janus Kinase (JAK) Inhibitors Consumption Value by Type (2019-2030)
  • 7.2 Europe Janus Kinase (JAK) Inhibitors Consumption Value by Application (2019-2030)
  • 7.3 Europe Janus Kinase (JAK) Inhibitors Market Size by Country
    • 7.3.1 Europe Janus Kinase (JAK) Inhibitors Consumption Value by Country (2019-2030)
    • 7.3.2 Germany Janus Kinase (JAK) Inhibitors Market Size and Forecast (2019-2030)
    • 7.3.3 France Janus Kinase (JAK) Inhibitors Market Size and Forecast (2019-2030)
    • 7.3.4 United Kingdom Janus Kinase (JAK) Inhibitors Market Size and Forecast (2019-2030)
    • 7.3.5 Russia Janus Kinase (JAK) Inhibitors Market Size and Forecast (2019-2030)
    • 7.3.6 Italy Janus Kinase (JAK) Inhibitors Market Size and Forecast (2019-2030)

8 Asia-Pacific

  • 8.1 Asia-Pacific Janus Kinase (JAK) Inhibitors Consumption Value by Type (2019-2030)
  • 8.2 Asia-Pacific Janus Kinase (JAK) Inhibitors Consumption Value by Application (2019-2030)
  • 8.3 Asia-Pacific Janus Kinase (JAK) Inhibitors Market Size by Region
    • 8.3.1 Asia-Pacific Janus Kinase (JAK) Inhibitors Consumption Value by Region (2019-2030)
    • 8.3.2 China Janus Kinase (JAK) Inhibitors Market Size and Forecast (2019-2030)
    • 8.3.3 Japan Janus Kinase (JAK) Inhibitors Market Size and Forecast (2019-2030)
    • 8.3.4 South Korea Janus Kinase (JAK) Inhibitors Market Size and Forecast (2019-2030)
    • 8.3.5 India Janus Kinase (JAK) Inhibitors Market Size and Forecast (2019-2030)
    • 8.3.6 Southeast Asia Janus Kinase (JAK) Inhibitors Market Size and Forecast (2019-2030)
    • 8.3.7 Australia Janus Kinase (JAK) Inhibitors Market Size and Forecast (2019-2030)

9 South America

  • 9.1 South America Janus Kinase (JAK) Inhibitors Consumption Value by Type (2019-2030)
  • 9.2 South America Janus Kinase (JAK) Inhibitors Consumption Value by Application (2019-2030)
  • 9.3 South America Janus Kinase (JAK) Inhibitors Market Size by Country
    • 9.3.1 South America Janus Kinase (JAK) Inhibitors Consumption Value by Country (2019-2030)
    • 9.3.2 Brazil Janus Kinase (JAK) Inhibitors Market Size and Forecast (2019-2030)
    • 9.3.3 Argentina Janus Kinase (JAK) Inhibitors Market Size and Forecast (2019-2030)

10 Middle East & Africa

  • 10.1 Middle East & Africa Janus Kinase (JAK) Inhibitors Consumption Value by Type (2019-2030)
  • 10.2 Middle East & Africa Janus Kinase (JAK) Inhibitors Consumption Value by Application (2019-2030)
  • 10.3 Middle East & Africa Janus Kinase (JAK) Inhibitors Market Size by Country
    • 10.3.1 Middle East & Africa Janus Kinase (JAK) Inhibitors Consumption Value by Country (2019-2030)
    • 10.3.2 Turkey Janus Kinase (JAK) Inhibitors Market Size and Forecast (2019-2030)
    • 10.3.3 Saudi Arabia Janus Kinase (JAK) Inhibitors Market Size and Forecast (2019-2030)
    • 10.3.4 UAE Janus Kinase (JAK) Inhibitors Market Size and Forecast (2019-2030)

11 Market Dynamics

  • 11.1 Janus Kinase (JAK) Inhibitors Market Drivers
  • 11.2 Janus Kinase (JAK) Inhibitors Market Restraints
  • 11.3 Janus Kinase (JAK) Inhibitors Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Janus Kinase (JAK) Inhibitors Industry Chain
  • 12.2 Janus Kinase (JAK) Inhibitors Upstream Analysis
  • 12.3 Janus Kinase (JAK) Inhibitors Midstream Analysis
  • 12.4 Janus Kinase (JAK) Inhibitors Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Janus Kinase (JAK) Inhibitors market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
    JAK inhibitors are increasingly being used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis because of its proven efficacy in the treatment of various chronic diseases.
    The high unmet need for the treatment of graft-versus-host disease (GVHD) has also encouraged market vendors to develop novel drugs for GVHD. The lack of approved therapies for the treatment of rare cancer indications will also boost the demand for JAK inhibitors.
    The Global Info Research report includes an overview of the development of the Janus Kinase (JAK) Inhibitors industry chain, the market status of Autoimmune Disorders (Ruxolitinib, Tofacitinib), Oncology (Ruxolitinib, Tofacitinib), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Janus Kinase (JAK) Inhibitors.
    Regionally, the report analyzes the Janus Kinase (JAK) Inhibitors markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Janus Kinase (JAK) Inhibitors market, with robust domestic demand, supportive policies, and a strong manufacturing base.
    Key Features:
    The report presents comprehensive understanding of the Janus Kinase (JAK) Inhibitors market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Janus Kinase (JAK) Inhibitors industry.
    The report involves analyzing the market at a macro level:
    Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Ruxolitinib, Tofacitinib).
    Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Janus Kinase (JAK) Inhibitors market.
    Regional Analysis: The report involves examining the Janus Kinase (JAK) Inhibitors market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
    Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Janus Kinase (JAK) Inhibitors market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
    The report also involves a more granular approach to Janus Kinase (JAK) Inhibitors:
    Company Analysis: Report covers individual Janus Kinase (JAK) Inhibitors players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
    Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Janus Kinase (JAK) Inhibitors This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Autoimmune Disorders, Oncology).
    Technology Analysis: Report covers specific technologies relevant to Janus Kinase (JAK) Inhibitors. It assesses the current state, advancements, and potential future developments in Janus Kinase (JAK) Inhibitors areas.
    Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Janus Kinase (JAK) Inhibitors market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
    Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
    Market Segmentation
    Janus Kinase (JAK) Inhibitors market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
    Market segment by Type
    Ruxolitinib
    Tofacitinib
    Oclacitinib
    Baricitinib
    Peficitinib
    Market segment by Application
    Autoimmune Disorders
    Oncology
    Market segment by players, this report covers
    Astellas Pharma, Inc.
    Eli Lilly and Co.
    Incyte Corp.
    Novartis AG
    Pfizer Inc.
    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Janus Kinase (JAK) Inhibitors product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Janus Kinase (JAK) Inhibitors, with revenue, gross margin and global market share of Janus Kinase (JAK) Inhibitors from 2019 to 2024.
    Chapter 3, the Janus Kinase (JAK) Inhibitors competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Janus Kinase (JAK) Inhibitors market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
    Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Janus Kinase (JAK) Inhibitors.
    Chapter 13, to describe Janus Kinase (JAK) Inhibitors research findings and conclusion.

    Buy now